GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
Subscribe To Our Newsletter & Stay Updated
